The Clinical Advisor

2 days ago | clinicaladvisor.com | Ron Goldberg

Sleep duration and sleep quality among older adults may be mediated by media use and demographic factors, according to study results presented at the American Psychiatric Association Annual Meeting, held virtually from May 17 to 21, 2025, in Los Angeles, California. Researchers sought to describe media-use preferences among older adults and how that usage impacts sleep duration and quality.

1 week ago | clinicaladvisor.com | Erin Clancy

The US Food and Drug Administration (FDA) is adopting a new regulatory framework that will change the criteria for approval of COVID-19 vaccines and ultimately limit who can be vaccinated, according to a viewpoint by FDA officials that was published in The New England Journal of Medicine.1 The FDA will continue to evaluate individual applications for COVID-19 vaccines on a case-by-case basis, but the agency will adopt different standards for approval according to the patient populations...

2 weeks ago | clinicaladvisor.com | Nikki Kean

Colonel James J. Jones, PhD, PA-C, was named ‘PA of the Year’ during the American Association of Physician Associates (AAPA) annual meeting, held from May 16 to 20, 2025, in Denver, Colorado. Dr Jones was honored “for his significant contributions to military medicine, public health initiatives, and the advancement of the physician associate (PA) profession,” announced AAPA.

2 weeks ago | clinicaladvisor.com | Jaymin Kang

The Food and Drug Administration (FDA) has approved Nuvaxovid™ (COVID-19 Vaccine, Adjuvanted) for active immunization to prevent COVID-19 caused by SARS-Cov-2 in adults 65 years and older and individuals 12 through 64 years who have at least 1 underlying condition that puts them at high risk for severe outcomes from COVID-19. Nuvaxovid is a recombinant protein-based COVID-19 vaccine that includes a proprietary adjuvant to enhance and prolong immune responses.

2 weeks ago | clinicaladvisor.com | Jaymin Kang

Zevtera® (ceftobiprole medocaril sodium for injection) is now available for the treatment of: adults with Staphylococcus aureus bloodstream infections (bacteremia; SAB), including those with right-sided infective endocarditis; adults with acute bacterial skin and skin structure infections (ABSSSI); and adult and pediatric patients 3 months to less than 18 years of age with community-acquired bacterial pneumonia (CABP).